Study of vicagrel for heart attack patients getting stents
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new medicine called vicagrel for people who have had a heart attack or unstable angina and are getting a stent. The goal is to see if it works better than standard treatments to prevent future heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have been diagnosed with a heart attack or unstable angina and are scheduled to have a stent placed
- You are willing to sign a consent form and follow the study schedule
- You are not expected to live less than 12 months due to other illnesses
- You do not have severe liver disease (for example, cirrhosis or very high liver enzymes)
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to improve how doctors monitor and guide treatment for people with heart disease who have had a stent placed. It focuses on finding the best ways to manage blood-thinning medications to reduce risks of bleeding and clotting.
This trial tests a new way of taking blood thinners after getting a stent. Instead of staying on two blood thinners for a long time, you switch earlier to just one (ticagrelor). This might reduce bleeding risks while still protecting against heart problems.
This trial tests whether a lower dose of the blood thinner ticagrelor works better than clopidogrel in people with stable coronary artery disease who are getting a planned stent. It aims to find which drug is safer and more effective for preventing future heart problems.
This study tests if a single blood thinner (ticagrelor) works well enough after getting a heart stent, instead of the usual two blood thinners. It may simplify your daily medication routine.
This trial studies ways to reduce bleeding in people after a stent procedure (PCI) who have been taking two anti-platelet medicines (aspirin plus prasugrel or ticagrelor) for a set amount of time. It may help find a safer plan for preventing blood clots while lowering bleeding risk.
This study compares ticagrelor taken at a lower dose versus regular aspirin to help prevent future heart attacks in people who recently had a stent placed after acute coronary syndrome. You may qualify if you’re considered “high risk” for new blockages or clots and can take dual anti-platelet therapy for 12 months.
Hear when a new Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.